KR20230025054A - Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. - Google Patents
Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. Download PDFInfo
- Publication number
- KR20230025054A KR20230025054A KR1020210107041A KR20210107041A KR20230025054A KR 20230025054 A KR20230025054 A KR 20230025054A KR 1020210107041 A KR1020210107041 A KR 1020210107041A KR 20210107041 A KR20210107041 A KR 20210107041A KR 20230025054 A KR20230025054 A KR 20230025054A
- Authority
- KR
- South Korea
- Prior art keywords
- preventing
- allergic diseases
- leaf extract
- horsetail
- pharmaceutical composition
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 68
- 208000026935 allergic disease Diseases 0.000 title claims abstract description 53
- 239000000203 mixture Substances 0.000 title claims abstract description 30
- 241000195950 Equisetum arvense Species 0.000 title claims abstract description 12
- 239000005768 Equisetum arvense L. Substances 0.000 title claims abstract description 12
- 210000003630 histaminocyte Anatomy 0.000 claims abstract description 46
- 206010020751 Hypersensitivity Diseases 0.000 claims abstract description 25
- 230000007815 allergy Effects 0.000 claims abstract description 13
- 230000001404 mediated effect Effects 0.000 claims abstract description 6
- 241000195955 Equisetum hyemale Species 0.000 claims description 56
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 235000013376 functional food Nutrition 0.000 claims description 13
- 230000036541 health Effects 0.000 claims description 12
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 201000010099 disease Diseases 0.000 claims description 10
- 238000000605 extraction Methods 0.000 claims description 9
- 210000003491 skin Anatomy 0.000 claims description 9
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 claims description 8
- 239000004480 active ingredient Substances 0.000 claims description 7
- 239000002904 solvent Substances 0.000 claims description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 208000004760 Tenosynovitis Diseases 0.000 claims description 5
- 208000003455 anaphylaxis Diseases 0.000 claims description 5
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 4
- 208000001640 Fibromyalgia Diseases 0.000 claims description 4
- 206010034464 Periarthritis Diseases 0.000 claims description 4
- 208000021386 Sjogren Syndrome Diseases 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- 208000006673 asthma Diseases 0.000 claims description 4
- 201000008937 atopic dermatitis Diseases 0.000 claims description 4
- 230000002265 prevention Effects 0.000 claims description 4
- 206010002199 Anaphylactic shock Diseases 0.000 claims description 3
- 206010002556 Ankylosing Spondylitis Diseases 0.000 claims description 3
- 206010010744 Conjunctivitis allergic Diseases 0.000 claims description 3
- 208000011231 Crohn disease Diseases 0.000 claims description 3
- 206010012442 Dermatitis contact Diseases 0.000 claims description 3
- 206010013700 Drug hypersensitivity Diseases 0.000 claims description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 208000004262 Food Hypersensitivity Diseases 0.000 claims description 3
- 206010016946 Food allergy Diseases 0.000 claims description 3
- 208000007882 Gastritis Diseases 0.000 claims description 3
- 201000005569 Gout Diseases 0.000 claims description 3
- 201000002481 Myositis Diseases 0.000 claims description 3
- 206010068319 Oropharyngeal pain Diseases 0.000 claims description 3
- 206010033078 Otitis media Diseases 0.000 claims description 3
- 201000007100 Pharyngitis Diseases 0.000 claims description 3
- 206010035664 Pneumonia Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 208000007107 Stomach Ulcer Diseases 0.000 claims description 3
- 208000000491 Tendinopathy Diseases 0.000 claims description 3
- 206010043255 Tendonitis Diseases 0.000 claims description 3
- 208000024780 Urticaria Diseases 0.000 claims description 3
- 208000002205 allergic conjunctivitis Diseases 0.000 claims description 3
- 208000024998 atopic conjunctivitis Diseases 0.000 claims description 3
- 208000037976 chronic inflammation Diseases 0.000 claims description 3
- 206010009887 colitis Diseases 0.000 claims description 3
- 208000010247 contact dermatitis Diseases 0.000 claims description 3
- 201000003146 cystitis Diseases 0.000 claims description 3
- 201000005311 drug allergy Diseases 0.000 claims description 3
- 235000020932 food allergy Nutrition 0.000 claims description 3
- 201000005917 gastric ulcer Diseases 0.000 claims description 3
- 208000014617 hemorrhoid Diseases 0.000 claims description 3
- 208000006454 hepatitis Diseases 0.000 claims description 3
- 231100000283 hepatitis Toxicity 0.000 claims description 3
- 206010025135 lupus erythematosus Diseases 0.000 claims description 3
- 201000006417 multiple sclerosis Diseases 0.000 claims description 3
- 201000008383 nephritis Diseases 0.000 claims description 3
- 201000008482 osteoarthritis Diseases 0.000 claims description 3
- 201000001245 periodontitis Diseases 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 206010039083 rhinitis Diseases 0.000 claims description 3
- 201000004415 tendinitis Diseases 0.000 claims description 3
- 206010044008 tonsillitis Diseases 0.000 claims description 3
- 208000038016 acute inflammation Diseases 0.000 claims description 2
- 230000006022 acute inflammation Effects 0.000 claims description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 2
- 201000003068 rheumatic fever Diseases 0.000 claims description 2
- 230000006020 chronic inflammation Effects 0.000 claims 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 abstract description 34
- 229960001340 histamine Drugs 0.000 abstract description 17
- 102000004127 Cytokines Human genes 0.000 abstract description 11
- 108090000695 Cytokines Proteins 0.000 abstract description 11
- 230000000694 effects Effects 0.000 description 18
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 13
- 239000011575 calcium Substances 0.000 description 13
- 229910052791 calcium Inorganic materials 0.000 description 13
- 210000004027 cell Anatomy 0.000 description 13
- 239000003814 drug Substances 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 229940079593 drug Drugs 0.000 description 11
- 230000003834 intracellular effect Effects 0.000 description 11
- 235000013305 food Nutrition 0.000 description 8
- 102000004388 Interleukin-4 Human genes 0.000 description 7
- 108090000978 Interleukin-4 Proteins 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 6
- 208000030961 allergic reaction Diseases 0.000 description 6
- 239000003112 inhibitor Substances 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 230000009471 action Effects 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 235000013373 food additive Nutrition 0.000 description 5
- 239000002778 food additive Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000008187 granular material Substances 0.000 description 5
- 230000002757 inflammatory effect Effects 0.000 description 5
- 201000004624 Dermatitis Diseases 0.000 description 4
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 4
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 238000012790 confirmation Methods 0.000 description 4
- 231100000135 cytotoxicity Toxicity 0.000 description 4
- 230000003013 cytotoxicity Effects 0.000 description 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 4
- 229960003957 dexamethasone Drugs 0.000 description 4
- 108010042617 dinitrophenyl-human serum albumin conjugate Proteins 0.000 description 4
- 235000003599 food sweetener Nutrition 0.000 description 4
- -1 for example Substances 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 239000000546 pharmaceutical excipient Substances 0.000 description 4
- 239000003765 sweetening agent Substances 0.000 description 4
- 238000005406 washing Methods 0.000 description 4
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 3
- 238000002965 ELISA Methods 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000002835 absorbance Methods 0.000 description 3
- 238000007796 conventional method Methods 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 210000005069 ears Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 206010002198 Anaphylactic reaction Diseases 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 102000009438 IgE Receptors Human genes 0.000 description 2
- 108010073816 IgE Receptors Proteins 0.000 description 2
- 108010002386 Interleukin-3 Proteins 0.000 description 2
- 102100039064 Interleukin-3 Human genes 0.000 description 2
- 108010002616 Interleukin-5 Proteins 0.000 description 2
- 102000000743 Interleukin-5 Human genes 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 102000035195 Peptidases Human genes 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 210000001744 T-lymphocyte Anatomy 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000013566 allergen Substances 0.000 description 2
- 230000036783 anaphylactic response Effects 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 235000013361 beverage Nutrition 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 210000000170 cell membrane Anatomy 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 208000037893 chronic inflammatory disorder Diseases 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000001766 physiological effect Effects 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 235000021067 refined food Nutrition 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 102000003390 tumor necrosis factor Human genes 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- HVAUUPRFYPCOCA-AREMUKBSSA-N 2-O-acetyl-1-O-hexadecyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCOC[C@@H](OC(C)=O)COP([O-])(=O)OCC[N+](C)(C)C HVAUUPRFYPCOCA-AREMUKBSSA-N 0.000 description 1
- YJIYWYAMZFVECX-UHFFFAOYSA-N 2-[N-[2-(acetyloxymethoxy)-2-oxoethyl]-2-[2-[2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]anilino]acetic acid acetyloxymethyl ester Chemical group CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O YJIYWYAMZFVECX-UHFFFAOYSA-N 0.000 description 1
- AZKSAVLVSZKNRD-UHFFFAOYSA-M 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide Chemical compound [Br-].S1C(C)=C(C)N=C1[N+]1=NC(C=2C=CC=CC=2)=NN1C1=CC=CC=C1 AZKSAVLVSZKNRD-UHFFFAOYSA-M 0.000 description 1
- 241000251468 Actinopterygii Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- FTEDXVNDVHYDQW-UHFFFAOYSA-N BAPTA Chemical compound OC(=O)CN(CC(O)=O)C1=CC=CC=C1OCCOC1=CC=CC=C1N(CC(O)=O)CC(O)=O FTEDXVNDVHYDQW-UHFFFAOYSA-N 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 101800004538 Bradykinin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108020005199 Dehydrogenases Proteins 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000011511 Diospyros Nutrition 0.000 description 1
- 244000236655 Diospyros kaki Species 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 244000085625 Equisetum Species 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 description 1
- 208000034507 Haematemesis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003814 Interleukin-10 Human genes 0.000 description 1
- 108090000174 Interleukin-10 Proteins 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 102000004889 Interleukin-6 Human genes 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 102000004890 Interleukin-8 Human genes 0.000 description 1
- 108090001007 Interleukin-8 Proteins 0.000 description 1
- 102100035792 Kininogen-1 Human genes 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 102000016611 Proteoglycans Human genes 0.000 description 1
- 108010067787 Proteoglycans Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010070834 Sensitisation Diseases 0.000 description 1
- 108010071390 Serum Albumin Proteins 0.000 description 1
- 102000007562 Serum Albumin Human genes 0.000 description 1
- 244000046109 Sorghum vulgare var. nervosum Species 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 108010039445 Stem Cell Factor Proteins 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 244000299461 Theobroma cacao Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- 241000592342 Tracheophyta Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- PTPUOMXKXCCSEN-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-dichloro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(Cl)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(Cl)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O PTPUOMXKXCCSEN-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 229940030225 antihemorrhagics Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 235000015241 bacon Nutrition 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000001164 bioregulatory effect Effects 0.000 description 1
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000000480 calcium channel blocker Substances 0.000 description 1
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 description 1
- 239000001354 calcium citrate Substances 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000007963 capsule composition Substances 0.000 description 1
- 230000020411 cell activation Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 235000013985 cinnamic acid Nutrition 0.000 description 1
- 229930016911 cinnamic acid Natural products 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 231100000263 cytotoxicity test Toxicity 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- PXEDJBXQKAGXNJ-QTNFYWBSSA-L disodium L-glutamate Chemical compound [Na+].[Na+].[O-]C(=O)[C@@H](N)CCC([O-])=O PXEDJBXQKAGXNJ-QTNFYWBSSA-L 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000012757 fluorescence staining Methods 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 201000005298 gastrointestinal allergy Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000012812 general test Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 150000002327 glycerophospholipids Chemical class 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000028709 inflammatory response Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 210000001821 langerhans cell Anatomy 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 1
- 235000019462 natural additive Nutrition 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- ZWLUXSQADUDCSB-UHFFFAOYSA-N phthalaldehyde Chemical compound O=CC1=CC=CC=C1C=O ZWLUXSQADUDCSB-UHFFFAOYSA-N 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000008313 sensitization Effects 0.000 description 1
- 229940076279 serotonin Drugs 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 239000000892 thaumatin Substances 0.000 description 1
- 235000010436 thaumatin Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RZWIIPASKMUIAC-VQTJNVASSA-N thromboxane Chemical compound CCCCCCCC[C@H]1OCCC[C@@H]1CCCCCCC RZWIIPASKMUIAC-VQTJNVASSA-N 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 235000013337 tricalcium citrate Nutrition 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/11—Pteridophyta or Filicophyta (ferns)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/304—Foods, ingredients or supplements having a functional effect on health having a modulation effect on allergy and risk of allergy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Pulmonology (AREA)
- Medical Informatics (AREA)
- Immunology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
본 발명은 쇠뜨기(Equisetum arvense L.) 잎 추출물을 유효성분으로 함유하는 알레르기 질환 예방 또는 치료용 조성물에 관한 것이다.The present invention is horsetail ( Equisetum It relates to a composition for preventing or treating allergic diseases containing an arvense L.) leaf extract as an active ingredient.
알레르기(allergy)란, 광범위하고 복잡한 병리적 현상의 총화로 면역반응에 근거한 생체의 전신적 또는 국소적인 장애이다. 인체에 나타나는 알레르기는 면역 기전에 따라 Ⅰ, Ⅱ, Ⅲ 및 Ⅳ형으로 분류되며, 이 중에서 즉시형 과민반응에 속하는 Ⅰ형 알레르기가 임상에서 중요한 부분을 차지하고 있으며, 아토피성 피부염, 알레르기성 비염, 기관지 천식, 고초열 및 화분증 등이 여기에 속한다.Allergy is a total of extensive and complex pathological phenomena, and is a systemic or local disorder of a living body based on an immune response. Allergies appearing in the human body are classified into types Ⅰ, Ⅱ, Ⅲ and Ⅳ depending on the immune mechanism. These include asthma, hay fever and hay fever.
1953년경 Ⅰ형 알레르기는 비만세포의 활성화에 의해 일어나며, 이러한 비만세포의 과립에는 염증반응의 매개체인 히스타민(histamine)이 다량 함유되어 있음이 알려졌다. 알레르기 반응이 일어날 때 비만세포에서 히스타민이 방출되는 현상이 발견된 후에 이 기전을 규명하던 중, 이시자까(Ishizaka)의 면역글로불린 E(immunoglobulin E, IgE)의 발견은 비만세포가 즉시형 알레르기 반응에 관여함을 밝히는 중요한 계기가 되었다. 즉, 비만세포 표면에는 IgE 고친화성 수용체가 있으며, 이 수용체에 IgE가 결합한 후 다시 항원이 결합하여 가교가 형성되면 탈과립반응이 유발되어 과립 내용물인 히스타민, 세로토닌(serotonin), 브라드키닌(bradykinin) 등과 같은, 합성되어 저장되어 있던 매개물질(preformed mediator)과, 프로테아제(protease), 프로테오글리칸(proteoglycan) 등이 동시에 방출되는 것이다.Around 1953, it was known that type I allergy is caused by the activation of mast cells, and that the granules of these mast cells contain a large amount of histamine, a mediator of an inflammatory response. After the discovery of the release of histamine from mast cells when an allergic reaction occurs, while investigating this mechanism, Ishizaka's discovery of immunoglobulin E (IgE) led to the discovery that mast cells respond to immediate-type allergic reactions. It served as an important opportunity to reveal involvement. That is, there is an IgE high-affinity receptor on the surface of mast cells, and when IgE binds to this receptor and antigen binds again to form a cross-link, a degranulation reaction is induced and the contents of the granule, such as histamine, serotonin, and bradykinin, etc. The same, synthesized and stored mediators (preformed mediators), proteases, proteoglycans, etc. are simultaneously released.
1970년대 이후 새로운 지질성의 염증 매개체에 대해 연구 결과가 보고되기 시작하였으며, 이들은 세포의 활성화에 동반하여 세포막 인지질로부터 생산된 프로스타그란딘류(prostaglandins), 류코트리엔류(leukotriens), 트롬복산(thromboxane), 글리세로포스포리피드(glycerophospholipids) 유도체인 PAF(platelet activating factor) 등으로 다양한 생리활성을 나타내는 신생 매개체들로서 Ⅰ형 알레르기 반응을 포함한 각종의 염증 반응에 관여함이 밝혀졌다. 이러한 지질성 매개체는 IgE 수용체가 가교를 형성할 때 비만세포에서 탈과립반응과 병행해서 생산, 방출된다.Since the 1970s, research results on new lipid-based inflammatory mediators have been reported, and these include prostaglandins, leukotriens, thromboxane, and glyceroproteins produced from cell membrane phospholipids accompanied by cell activation. PAF (platelet activating factor), a derivative of glycerophospholipids, is a new mediator that exhibits various physiological activities and has been found to be involved in various inflammatory reactions including type I allergic reactions. These lipid mediators are produced and released in parallel with degranulation in mast cells when IgE receptors form cross-links.
즉, Ⅰ형 알레르기는 비만세포의 활성화에 의해 방출되는 과립내용물인 활성아민류와 프로테아제류, 세포막 인지질에서 생성되는 지질성 매개체, 면역반응의 조절인자로 잘 알려진 IL-3(비만세포 증식인자), IL-4, IL-5과 같은 사이토카인(cytokine) 등이 관련되어 일어나는 생체의 자연스러운 현상이라고 종합할 수 있다.In other words, type I allergy is caused by active amines and proteases, which are granular contents released by activation of mast cells, lipid mediators produced from cell membrane phospholipids, IL-3 (mast cell growth factor), which is well known as a modulator of immune response, It can be summed up as a natural phenomenon in the body that occurs in association with cytokines such as IL-4 and IL-5.
또한, 알레르기 항원에 피부가 노출되면 랑게르한스 세포의 표면에 있는 IgE 수용체에 항원 특이 IgE가 결합하고, 이 항원의 표면에 있는 T 세포에 전달되어 T세포가 활성화된다. 이 경우 정상과 달리 알레르기성 피부질환, 특히, 아토피 피부염에서는 Th2가 활성화되어 IL-4, IL-5, IL-6, IL-8, IL-10 및 IL-13 등의 사이토카인이 분비되고, 그 결과 B 세포에서 IgE의 생성이 촉진되어 활성화되어있는 비만세포의 탈과립을 촉진시켜 사이토카인과 히스타민이 유리된다.In addition, when the skin is exposed to an allergen, antigen-specific IgE binds to an IgE receptor on the surface of Langerhans cells, and is transmitted to T cells on the surface of the antigen to activate the T cells. In this case, unlike normal allergic skin diseases, especially atopic dermatitis, Th2 is activated and cytokines such as IL-4, IL-5, IL-6, IL-8, IL-10 and IL-13 are secreted, As a result, the production of IgE in B cells is promoted, and the degranulation of activated mast cells is promoted, and cytokines and histamine are released.
현재 임상적으로 사용되고 있는 알레르기 치료 약물은 작용기전에 따라 탈과립저해제, 화학전달물질 작용억제제, 화학전달물질 합성저해제 등으로 대별할 수 있다. 이러한 약물들 중 화학전달물질 작용억제제와 화학전달물질 합성저해제의 경우 약물작용점이 비교적 확실하지만, 탈과립저해제의 경우 그 작용기전이 불분명한 상태이며, 이들 약물들은 장기간 투여에 의해 여러 가지 부작용을 초래할 수 있다. 이에 따라Ⅰ형 알레르기의 치료를 위해 비만세포에서 이들 생리활성 물질의 생산 및 유리에 대한 작용기전을 밝히고, 장기복용에 따른 부작용을 최소화할 수 있는 물질의 개발이 대단히 중요하다고 할 수 있다. Allergy drugs that are currently used clinically can be roughly classified into degranulation inhibitors, chemical transmitter inhibitors, and chemical transmitter synthesis inhibitors according to their mechanism of action. Among these drugs, chemical transmitter action inhibitors and chemical transmitter synthesis inhibitors have a relatively certain point of action, but in the case of degranulation inhibitors, their mechanism of action is unclear, and these drugs can cause various side effects by long-term administration. there is. Accordingly, for the treatment of type I allergy, it is very important to develop substances that can minimize the side effects of long-term use and to reveal the mechanism of action for the production and release of these physiologically active substances in mast cells.
본 발명의 목적은 우수한 비만세포 탈과립 억제 효과를 가진 천연물을 이용한 알레르기 질환 예방, 개선, 또는 치료 조성물을 제공하는 데에 있다.An object of the present invention is to provide a composition for preventing, improving, or treating allergic diseases using natural products having an excellent mast cell degranulation inhibitory effect.
상기의 목적을 달성하기 위하여, 본 발명은 쇠뜨기(Equisetum arvense L.) 잎 추출물을 유효성분으로 함유하는 알레르기 질환 예방 또는 치료용 약학 조성물을 제공한다.In order to achieve the above object, the present invention provides a pharmaceutical composition for preventing or treating allergic diseases containing horsetail ( Equisetum arvense L.) leaf extract as an active ingredient.
또한, 본 발명은 쇠뜨기(Equisetum arvense L.) 잎 추출물을 유효성분으로 함유하는 알레르기 질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention is horsetail ( Equisetum arvense L.) provides a health functional food composition for preventing or improving allergic diseases containing leaf extract as an active ingredient.
본 발명에 따른 쇠뜨기(Equisetum arvense L.) 잎 추출물은 비만세포로부터의 히스타민 방출을 억제하고, 알레르기를 유발하는 사이토카인 발현을 억제하는 효과를 가지는 바, 이를 이용하여 비만세포 매개의 다양한 알레르기 질환을 효과적으로 예방, 개선 또는 치료할 수 있다.Horsetail according to the present invention ( Equisetum arvense L.) leaf extract inhibits the release of histamine from mast cells and has the effect of suppressing the expression of cytokines that cause allergy, and thus, various allergic diseases mediated by mast cells can be effectively prevented, improved, or treated. there is.
또한, 본 발명에 따른 조성물은 상기 쇠뜨기 잎 추출물과 같은 천연물의 추출물을 이용함으로써, 부작용이 적고 보다 안전하게 알레르기 질환을 예방, 개선 또는 치료할 수 있다. In addition, the composition according to the present invention can prevent, improve, or treat allergic diseases more safely with fewer side effects by using a natural extract such as the horsetail leaf extract.
도 1은 인간 비만세포주 RBL-2H3 세포에서 히스타민 유리 억제에 대한 쇠뜨기 잎 추출물의 효과를 확인한 그래프이다 (EELEA : 쇠뜨기 잎 추출물, Dexa : 덱사메타손(dexamethasone)).
도 2는 RBL-2H3 세포에서 세포 내 칼슘 감소에 대한 쇠뜨기 잎 추출물의 효과를 확인한 그래프이다.
도 3은 RBL-2H3 세포에서 쇠뜨기 잎 추출물 농도별 TNF-α 및 IL-4 사이토카인의 분비량 변화를 확인한 그래프이다.
도 4는 국소 피부 알레르기 반응에 대한 쇠뜨기 잎 추출물의 효과를 확인한 것으로, A는 수동형 국소 피부 알레르기 반응(passive cutaneous anaphylaxis, PCA)을 통해 쇠뜨기 잎 추출물의 피부 알레르기에 대한 효과를 확인한 이미지며, B는 수동형 국소 피부 알레르기 반응(PCA)을 통해 쇠뜨기 잎 추출물의 농도별 피부 알레르기에 대한 귀의 색 변화를 확인한 그래프이다.
도 5은 RBL-2H3 세포에서 쇠뜨기 잎 추출물의 세포독성을 확인한 그래프이다.1 is a graph confirming the effect of horsetail leaf extract on histamine release inhibition in human mast cell line RBL-2H3 cells (EELEA: horsetail leaf extract, Dexa: dexamethasone).
Figure 2 is a graph confirming the effect of horsetail leaf extract on intracellular calcium reduction in RBL-2H3 cells.
Figure 3 is a graph confirming the change in the secretion amount of TNF-α and IL-4 cytokines for each concentration of horsetail leaf extract in RBL-2H3 cells.
Figure 4 confirms the effect of horsetail leaf extract on local skin allergic reaction, A is an image confirming the effect of horsetail leaf extract on skin allergy through passive cutaneous anaphylaxis (PCA), and B is It is a graph confirming the color change of the ear for skin allergy by concentration of horsetail leaf extract through passive local skin allergy (PCA).
5 is a graph confirming the cytotoxicity of horsetail leaf extract in RBL-2H3 cells.
이하, 본 발명을 상세하게 설명하기로 한다.Hereinafter, the present invention will be described in detail.
본 발명자들은 쇠뜨기 잎 추출물의 비만세포 유래 알레르기 질환에 대한 효과를 연구한 결과, 상기 추출물이 비만세포로부터의 히스타민 유리를 억제하고, 염증 유발 사이토카인인 종양괴사인자(TNF)-α 및 IL-4 유전자의 발현을 억제함을 확인함으로써, 본 발명을 완성하였다.The present inventors studied the effects of horsetail leaf extract on mast cell-derived allergic diseases, and as a result, the extract inhibited the release of histamine from mast cells, and tumor necrosis factor (TNF)-α and IL-4, which are inflammatory cytokines, were found. By confirming that the expression of the gene was inhibited, the present invention was completed.
본 발명은 쇠뜨기(Equisetum arvense L.) 추출물, 보다 바람직하게는 쇠뜨기 잎 추출물을 유효성분으로 함유하는 알레르기 질환 예방 또는 치료용 약학 조성물을 제공한다.The present invention is horsetail ( Equisetum arvense L.) extract, more preferably a pharmaceutical composition for preventing or treating allergic diseases containing horsetail leaf extract as an active ingredient.
본 명세서에서, "쇠뜨기(Equisetum arvense L.)"란, '뱀밥', '토필', '준솔' 등으로 불리기도 하는 관다발식물 속새목 속새과의 여러해살이풀로, 포자로 번식하는 양치식물이다. 전국의 뜰, 밭뚝, 야산 등에서 자라며, 땅에서 실리콘을 흡수한다. 민간에서 생식줄기는 나물로 먹으며, 영양줄기는 약재로도 사용하였다. 쇠뜨기는 열을 내려주고 소변을 잘 나오게 하는 성질이 있어 몸에 열이 많은 사람과 코피, 토혈, 월경과다 등에 지혈약으로 써왔으며, 배설을 촉진하는 이뇨제로도 사용하나, 이의 알레르기 질환 치료 효능에 대해서는 알려진 바 없다.In this specification, "horsetail ( Equisetum arvense L.)" is a perennial plant belonging to the vascular plant Horseshoeidae, which is also called 'Bambop', 'Topil', 'Junsol', etc., and is a fern plant that propagates by spores. It grows and absorbs silicon from the ground. In the private sector, the reproductive stem is eaten as a vegetable, and the nutritive stem is also used as a medicine. It has been used as a hemostatic agent for hematemesis and menstruation, and is also used as a diuretic to promote excretion, but nothing is known about its efficacy in treating allergic diseases.
본 명세서에서, "추출물"이란, 추출 방법, 추출 용매, 추출된 성분 또는 추출물의 형태를 불문하고 천연물의 성분을 뽑아냄으로써 얻어진 물질을 의미하는 것으로, 천연물의 성분을 뽑아내어 얻어진 물질을 추출 후 다른 방법으로 가공 또는 처리하여 얻어질 수 있는 물질을 모두 포함할 수 있다.As used herein, "extract" refers to a substance obtained by extracting a component of a natural substance regardless of the extraction method, extraction solvent, extracted component, or the form of the extract. It may include all materials that can be obtained by processing or processing by the method.
상기 추출물은 당해 기술 분야에서 통상적으로 사용하는 방법에 따라 추출될 수 있고, 예를 들어, 열수 추출법, 초음파 추출법, 여과법, 환류 추출법 등이 있으며, 이들은 단독으로 수행되거나 2종 이상의 방법을 병용하여 수행될 수 있다.The extract may be extracted according to a method commonly used in the art, for example, hot water extraction, ultrasonic extraction, filtration, reflux extraction, etc., which are performed alone or in combination with two or more methods. It can be.
본 발명에 있어서, 상기 추출물은 물, C1-C4 알코올 또는 이의 혼합물을 추출용매로 하여 추출된 것일 수 있고, 바람직하게는 60 내지 80℃의 물을 추출용매로 하여 추출된 것일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the extract may be extracted using water, C1-C4 alcohol, or a mixture thereof as an extraction solvent, preferably extracted using water at 60 to 80 ° C. as an extraction solvent, but is limited thereto it is not going to be
상기 추출물은 쇠뜨기의 포자낭이삭, 줄기, 잎, 또는 이들 부위의 혼합물을 추출한 것일 수 있고, 바람직하게는 쇠뜨기의 잎을 추출한 것일 수 있으나, 이에 제한되는 것은 아니다.The extract may be obtained by extracting horsetail sporangia ears, stems, leaves, or a mixture of these parts, and may preferably be obtained by extracting horsetail leaves, but is not limited thereto.
본 발명에 있어서, 상기 조성물은 비만세포의 탈과립을 억제하고 항염증 활성을 가질 수 있다. 본 발명의 일 실시예에 따르면, 쇠뜨기 잎 추출물이 활성화된 비만세포에서 히스타민의 유리를 억제하고, 세포 내 칼슘의 양을 감소시켜 비만세포의 탈과립을 억제하며, 염증 유발 사이토카인인 TNF-α 및 IL-4의 발현을 억제하함을 확인할 수 있다. 또한, 국소적 피부 알레르기 반응을 억제하는 바, 상기 조성물은 알레르기 질환의 예방 또는 치료를 위해 사용될 수 있다.In the present invention, the composition may inhibit mast cell degranulation and have anti-inflammatory activity. According to one embodiment of the present invention, the horsetail leaf extract inhibits the release of histamine from activated mast cells, reduces the amount of intracellular calcium to inhibit mast cell degranulation, and inhibits the inflammatory cytokine TNF-α and It can be confirmed that the expression of IL-4 is inhibited. In addition, since it suppresses local skin allergic reactions, the composition can be used for preventing or treating allergic diseases.
본 발명에 있어서, 상기 알레르기 질환은 알레르기(allergy)에 의해 발생하는 질환으로, 바람직하게는 비만세포 매개의 알레르기 질환일 수 있다. 보다 상세하게는 접촉피부염, 아토피피부염, 천식, 알레르기성 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 아나필락틱 쇼크(anaphylactic shock), 다발성 경화증, 급성 염증, 만성 염증질환, 두드러기, 고초열, 소화관 알레르기, 약제 알레르기, 식품 알레르기 및 화분증으로 이루어진 군에서 선택되는 하나 이상일 수 있으나, 이에 제한되는 것은 아니다.In the present invention, the allergic disease is a disease caused by allergy, and preferably may be a mast cell-mediated allergic disease. More specifically, contact dermatitis, atopic dermatitis, asthma, allergic conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatoid fever, lupus, fibromyalgia (fibromyalgia), psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, anaphylactic shock, multiple sclerosis, acute It may be one or more selected from the group consisting of inflammation, chronic inflammatory disease, urticaria, hay fever, digestive tract allergy, drug allergy, food allergy, and hay fever, but is not limited thereto.
본 명세서에서, "예방"이란, 본 발명에 따른 조성물의 투여에 의해 알레르기 질환 또는 상기 질환의 적어도 하나 이상의 증상의 발생을 억제시키거나 발병을 지연시키는 모든 행위를 의미한다. 또한, 재발을 예방하거나 방지하기 위해 상기 질병에 차도가 있는 대상의 치료를 포함할 수 있다. In the present specification, "prevention" means any action that suppresses or delays the onset of allergic diseases or at least one symptom of the diseases by administration of the composition according to the present invention. It may also include treatment of subjects in remission of the disease to prevent or prevent relapse.
본 명세서에서, "치료"란, 본 발명에 따른 조성물의 투여에 의해 알레르기 질환 또는 상기 질환의 적어도 하나 이상의 증상을 완화, 감소 또는 소멸시키는 등 그 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.As used herein, "treatment" refers to all actions that improve or beneficially change the symptoms, such as alleviating, reducing or disappearing at least one symptom of an allergic disease or the disease by administration of the composition according to the present invention. .
본 명세서에서, "약학 조성물"이란, 본 발명의 목적상 알레르기 질환 또는 상기 질환의 적어도 하나 이상의 증상을 예방, 치료 또는 재발을 방지하기 위해 투여되는 것을 의미한다.In the present specification, "pharmaceutical composition" means that it is administered to prevent, treat, or prevent the recurrence of allergic diseases or at least one or more symptoms of the diseases for the purpose of the present invention.
본 발명에 따른 약학 조성물은 약학적 분야의 통상적인 방법에 따라 제조될 수 있다. 상기 약학 조성물은 제형에 따라 약학적으로 허용가능한 적절한 담체와 배합될 수 있고, 필요에 따라, 부형제, 희석제, 분산제, 유화제, 완충제, 안정제, 결합제, 붕해제, 용제 등을 더 포함하여 제조될 수 있다. 상기 적절한 담체 등은 본 발명에 따른 쇠뜨기 잎 추출물의 활성 및 특성을 저해하지 않는 것으로, 투여 형태 및 제형에 따라 달리 선택될 수 있다.The pharmaceutical composition according to the present invention can be prepared according to conventional methods in the pharmaceutical field. The pharmaceutical composition may be formulated with an appropriate pharmaceutically acceptable carrier according to the formulation and, if necessary, may further contain excipients, diluents, dispersants, emulsifiers, buffers, stabilizers, binders, disintegrants, solvents, and the like. there is. The appropriate carrier and the like do not inhibit the activity and characteristics of the horsetail leaf extract according to the present invention, and may be selected differently depending on the dosage form and formulation.
상기 약학 조성물은 어떠한 제형으로도 적용될 수 있고, 보다 상세하게는 통상의 방법에 따라 경구형 제형, 외용제, 좌제 및 멸균 주사용액의 비경구형 제형으로 제형화하여 사용될 수 있다.The pharmaceutical composition may be applied in any dosage form, and more specifically, it may be formulated and used in parenteral dosage forms such as oral dosage forms, external preparations, suppositories and sterile injection solutions according to conventional methods.
상기 경구형 제형 중 고형 제형은 정제, 환제, 산제, 과립제, 겔제, 캡슐제 등의 형태로, 적어도 하나 이상의 부형제, 예를 들면, 전분, 칼슘카보네이트, 수크로스, 락토오스, 솔비톨, 만니톨, 셀룰로오스, 젤라틴 등을 섞어 조제할 수 있고, 단순한 부형제 이외에 마그네슘 스테아레이트, 탈크 같은 윤활제들도 포함될 수 있다. 또한, 캡술제형의 경우 상기 언급한 물질 외에도 지방유와 같은 액체 담체를 더 포함할 수 있다.Among the oral dosage forms, the solid dosage form is in the form of tablets, pills, powders, granules, gels, capsules, etc., and includes at least one excipient, for example, starch, calcium carbonate, sucrose, lactose, sorbitol, mannitol, cellulose, It can be prepared by mixing gelatin, etc., and lubricants such as magnesium stearate and talc may be included in addition to simple excipients. In addition, in the case of a capsule formulation, a liquid carrier such as fatty oil may be further included in addition to the above-mentioned materials.
상기 경구형 제형 중 액상 제형은 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순 희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.Among the oral formulations, liquid formulations include suspensions, solutions for internal use, emulsions, syrups, etc. In addition to water and liquid paraffin, which are commonly used simple diluents, various excipients such as wetting agents, sweeteners, aromatics, and preservatives may be included. there is.
상기 비경구 제형은 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조 제제, 좌제가 포함될 수 있다. 비수성용제, 현탁제로는 프로필렌글리콜, 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다. 이에 제한되지 않고, 당해 기술 분야에 알려진 적합한 제제를 모두 사용 가능하다.The parenteral formulation may include a sterilized aqueous solution, a non-aqueous solvent, a suspension, an emulsion, a lyophilized formulation, and a suppository. Propylene glycol, polyethylene glycol, vegetable oils such as olive oil, and injectable esters such as ethyl oleate may be used as non-aqueous solvents and suspending agents. As a base for the suppository, witepsol, macrogol, Tween 61, cacao butter, laurin fat, glycerogeratin, and the like may be used. It is not limited thereto, and all suitable agents known in the art may be used.
또한, 본 발명에 따른 약학 조성물은 치료 효능의 증진을 위해 칼슘이나 비타민 등을 더 첨가할 수 있다. In addition, calcium or vitamins may be further added to the pharmaceutical composition according to the present invention to enhance therapeutic efficacy.
본 발명에 따른 약학 조성물에 있어서, 상기 약학 조성물은 약학적으로 유효한 양으로 투여될 수 있다. In the pharmaceutical composition according to the present invention, the pharmaceutical composition may be administered in a pharmaceutically effective amount.
본 명세서에서, "약학적으로 유효한 양"이란, 의학적 치료에 적용 가능한 합리적인 수혜/위험 비율로 질환을 치료하기에 충분하며 부작용을 일으키지 않을 정도의 양을 의미한다.In the present specification, "pharmaceutically effective amount" means an amount that is sufficient to treat a disease with a reasonable benefit/risk ratio applicable to medical treatment and does not cause side effects.
상기 약학 조성물의 유효 용량 수준은 사용 목적, 환자의 연령, 성별, 체중 및 건강 상태, 질환의 종류, 중증도, 약물의 활성, 약물에 대한 민감도, 투여 방법, 투여 시간, 투여 경로 및 배출 비율, 치료기간, 배합 또는 동시 사용되는 약물을 포함한 요소 및 기타 의학 분야에 잘 알려진 요소에 따라 달리 결정될 수 있다. 예를 들어, 일정하지는 않지만 일반적으로 0.001 내지 100mg/kg으로, 바람직하게는 0.01 내지 10mg/kg을 일일 1회 내지 수회 투여될 수 있다. 상기 투여량은 어떠한 면으로든 본 발명의 범위를 한정하는 것은 아니다.The effective dosage level of the pharmaceutical composition depends on the purpose of use, the patient's age, sex, weight and health condition, disease type, severity, drug activity, drug sensitivity, administration method, administration time, administration route and excretion rate, treatment Duration, combination, or factors including drugs used concurrently and other factors well known in the medical arts may be determined differently. For example, although not constant, generally 0.001 to 100 mg/kg, preferably 0.01 to 10 mg/kg, may be administered once or several times a day. The dosage is not intended to limit the scope of the present invention in any way.
상기 약학 조성물은 알레르기 질환이 발생할 수 있는 임의의 동물에 투여할 수 있고, 상기 동물은 예를 들어, 인간 및 영장류뿐만 아니라 소, 돼지, 말, 개 등의 가축 등을 포함할 수 있다.The pharmaceutical composition may be administered to any animal that may develop an allergic disease, and the animal may include, for example, humans and primates as well as livestock such as cattle, pigs, horses, and dogs.
상기 약학 조성물은 제제 형태에 따른 적당한 투여 경로로 투여될 수 있고, 목적 조직에 도달할 수 있는 한 경구 또는 비경구의 다양한 경로를 통하여 투여될 수 있다. 투여 방법은 특히 한정할 필요 없이, 예를 들면, 경구, 직장 또는 정맥, 근육, 피부 도포, 호흡기내 흡입, 자궁내 경막 또는 뇌혈관내(intracere-broventricular) 주사 등의 통상적인 방법으로 투여될 수 있다.The pharmaceutical composition may be administered by an appropriate administration route according to the formulation form, and may be administered through various oral or parenteral routes as long as it can reach the target tissue. The method of administration is not particularly limited, and may be administered by conventional methods such as oral, rectal or intravenous, intramuscular, skin application, intraventricular inhalation, intrauterine dural or intracerebroventricular injection. there is.
상기 약학 조성물은 알레르기 질환의 예방 또는 치료를 위하여 단독으로 사용될 수 있고, 수술 또는 다른 약물치료 등과 병용하여 사용될 수 있다.The pharmaceutical composition may be used alone for the prevention or treatment of allergic diseases, or may be used in combination with surgery or other drug treatment.
또한, 본 발명은 쇠뜨기(Equisetum arvense L.) 추출물, 보다 바람직하게는 쇠뜨기 잎 추출물을 유효성분으로 함유하는 알레르기 질환 예방 또는 개선용 건강기능식품 조성물을 제공한다.In addition, the present invention is horsetail ( Equisetum arvense L.) extract, more preferably a health functional food composition for preventing or improving allergic diseases containing horsetail leaf extract as an active ingredient.
상기 추출물은 물, C1-C4 알코올 또는 이의 혼합물을 추출용매로 하여 추출된 것일 수 있고, 바람직하게는 60 내지 80℃의 물을 추출용매로 하여 추출된 것일 수 있으나, 이에 제한되는 것은 아니다.The extract may be extracted using water, C1-C4 alcohol, or a mixture thereof as an extraction solvent, and preferably may be extracted using water at 60 to 80 ° C. as an extraction solvent, but is not limited thereto.
상기 추출물은 쇠뜨기의 포자낭이삭, 줄기, 잎, 또는 이들 부위의 혼합물을 추출한 것일 수 있고, 바람직하게는 쇠뜨기의 잎을 추출한 것일 수 있으나, 이에 제한되는 것은 아니다.The extract may be obtained by extracting horsetail sporangia ears, stems, leaves, or a mixture of these parts, and may preferably be obtained by extracting horsetail leaves, but is not limited thereto.
상기 조성물은 비만세포의 탈과립을 억제하고 항염증 활성을 가질 수 있으며, 국소적 피부 알레르기 반응을 억제하는 바, 상기 조성물은 알레르기 질환의 예방 또는 개선을 위해 사용될 수 있다.The composition may inhibit degranulation of mast cells, have anti-inflammatory activity, and suppress local skin allergic reactions, and thus, the composition may be used for preventing or improving allergic diseases.
상기 알레르기 질환은 바람직하게는 비만세포 매개의 알레르기 질환일 수 있으며, 보다 상세하게는 접촉피부염, 아토피피부염, 천식, 알레르기성 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 아나필락틱 쇼크(anaphylactic shock), 다발성 경화증, 급성 염증, 만성 염증질환, 두드러기, 고초열, 소화관 알레르기, 약제 알레르기, 식품 알레르기 및 화분증으로 이루어진 군에서 선택되는 하나 이상일 수 있으나, 이에 제한되는 것은 아니다.The allergic disease may preferably be a mast cell-mediated allergic disease, and more specifically, contact dermatitis, atopic dermatitis, asthma, allergic conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, and Crohn's disease. disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendinitis, tenosynovitis, peritendinitis, myositis, hepatitis, cystitis, nephritis, Sjogren's syndrome ( sjogren's syndrome), anaphylactic shock, multiple sclerosis, acute inflammation, chronic inflammatory disease, urticaria, hay fever, gastrointestinal allergy, drug allergy, food allergy, and hay fever. It is not limited.
이에 상응하는 특징들은 상술된 부분에서 대신할 수 있다.Corresponding features may be substituted in the foregoing.
본 명세서에서, "개선"이란, 본 발명에 따른 조성물에 의해 알레르기 질환, 또는 상기 질환의 적어도 하나 이상의 증상이 완화, 감소, 또는 소멸시키는 등 그 증세를 호전시키거나 이롭게 변경하는 모든 행위를 의미한다.In the present specification, "improvement" refers to all actions that improve or beneficially change the symptoms of an allergic disease, such as alleviating, reducing, or disappearing at least one symptom of an allergic disease or the disease by the composition according to the present invention. .
본 명세서에서, "건강기능식품"이란, 건강기능식품에 관한 법률 제6727호에 따른 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 제조 및 가공한 식품을 포함하며, 영양 공급 외에도 본 발명의 목적상 알레르기 질환의 예방, 생체 방어, 면역, 회복 등의 생체 조절 기능이 효율적으로 나타나도록 가공된 의학, 의료 효과가 높은 식품을 의미한다.In the present specification, "health functional food" includes food manufactured and processed using raw materials or ingredients having useful functionalities for the human body according to Health Functional Food Act No. 6727, and in addition to providing nutrition, the purpose of the present invention It refers to medicines and foods with high medical effects that are processed to efficiently display bioregulatory functions such as prevention of allergic diseases, biodefense, immunity, and recovery.
본 발명에 따른 건강기능식품은 알레르기 질환의 예방 또는 개선 목적으로, 분말, 과립, 정제, 캡슐, 시럽 또는 음료 등으로 제조될 수 있다. 상기 건강기능식품이 취할 수 있는 형태에는 제한이 없으며, 상기 약학 조성물과 동일한 방식으로 제제화되어 기능성 식품으로 이용하거나, 각종 식품에 첨가될 수 있다. For the purpose of preventing or improving allergic diseases, the health functional food according to the present invention may be prepared in the form of powder, granule, tablet, capsule, syrup or beverage. There is no limit to the form that the health functional food can take, and it can be formulated in the same way as the pharmaceutical composition and used as a functional food or added to various foods.
상기 건강기능식품은 통상적인 의미의 식품을 모두 포함할 수 있다. 예를 들어, 음료 및 각종 드링크, 과실 및 그의 가공식품(과일통조림, 잼 등), 어류, 육류 및 그 가공식품(햄, 베이컨 등), 빵류 및 면류, 쿠키 및 스낵류, 유제품(버터, 치즈 등) 등이 가능하며, 통상적인 의미에서의 기능성 식품을 모두 포함할 수 있다. 또한, 동물을 위한 사료로 이용되는 식품도 포함할 수 있다.The health functional food may include all foods in a conventional sense. For example, beverages and various drinks, fruits and their processed foods (canned fruit, jam, etc.), fish, meat and their processed foods (ham, bacon, etc.), breads and noodles, cookies and snacks, dairy products (butter, cheese, etc.) ) and the like, and may include all functional foods in a conventional sense. In addition, food used as feed for animals may also be included.
본 발명에 따른 건강기능식품 조성물은 당업계에서 통상적으로 사용되는 식품학적으로 허용 가능한 식품 첨가제(식품 첨가물) 및 적절한 기타 보조 성분을 더 포함하여 제조될 수 있다. 식품 첨가물로서의 적합 여부는 다른 규정이 없는 한, 식품의약품안전처에 승인된 식품첨가물공전의 총칙 및 일반시험법 등에 따라 해당 품목에 관한 규격 및 기준에 의하여 판정할 수 있다. 상기 '식품첨가물공전'에 수재된 품목으로는 예를 들어, 케톤류, 글리신, 구연산칼슘, 니코틴산, 계피산 등의 화학적 합성물; 감색소, 감초 추출물, 결정셀룰로오스, 고량색소, 구아검 등의 천연첨가물; L-글루타민산나트륨 제제, 면류첨가알칼리제, 보존료 제제, 타르색소제제 등의 혼합 제제류 등을 들 수 있다. The health functional food composition according to the present invention may be prepared by further including food chemically acceptable food additives (food additives) commonly used in the art and other appropriate auxiliary components. The suitability as a food additive can be determined according to the standards and standards for the item in accordance with the general rules of the Food Additive Code and general test methods approved by the Ministry of Food and Drug Safety, unless otherwise specified. Examples of the items listed in the 'Food Additive Code' include, for example, chemical compounds such as ketones, glycine, calcium citrate, nicotinic acid, and cinnamic acid; natural additives such as persimmon pigment, licorice extract, crystalline cellulose, kaoliang pigment, and guar gum; mixed preparations such as sodium L-glutamate preparations, noodle-added alkali preparations, preservative preparations, and tar color preparations; and the like.
상기 기타 보조 성분은 예를 들어, 향미제, 천연 탄수화물, 감미제, 비타민, 전해질, 착색제, 펙트산, 알긴산, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알콜, 탄산화제 등을 추가로 함유할 수 있다. 특히, 상기 천연 탄수화물로는 포도당, 과당과 같은 모노사카라이드, 말토스, 수크로오스와 같은 디사카라이드, 및 덱스트린, 사이클로덱스트린과 같은 폴리사카라이드, 자일리톨, 소르비톨, 에리트리톨 등의 당알콜을 사용할 수 있으며, 감미제로서는 타우마틴, 스테비아 추출물과 같은 천연 감미제나 사카린, 아스파르탐과 같은 합성 감미제 등을 사용할 수 있다.The other auxiliary ingredients include, for example, flavoring agents, natural carbohydrates, sweeteners, vitamins, electrolytes, colorants, pectic acid, alginic acid, organic acids, protective colloidal thickeners, pH adjusting agents, stabilizers, preservatives, glycerin, alcohols, carbonating agents, etc. may additionally contain. In particular, as the natural carbohydrate, monosaccharides such as glucose and fructose, disaccharides such as maltose and sucrose, polysaccharides such as dextrin and cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol may be used. As the sweetener, natural sweeteners such as thaumatin and stevia extract or synthetic sweeteners such as saccharin and aspartame may be used.
본 발명에 따른 건강기능식품에 함유된 상기 추출물의 유효 용량은 알레르기 질환의 예방 또는 개선 등 그 사용 목적에 따라 적절하게 조절될 수 있다. The effective dose of the extract contained in the health functional food according to the present invention may be appropriately adjusted according to the purpose of use, such as preventing or improving allergic diseases.
상기 건강기능식품 조성물은 식품을 원료로 하여 일반 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 알레르기 질환의 예방 또는 개선을 위한 보조제로 섭취될 수 있다.The health functional food composition uses food as a raw material and has the advantage of not having side effects that can occur when taking general medicines for a long time, and has excellent portability, so it can be taken as an adjuvant for preventing or improving allergic diseases.
이하, 본 발명의 이해를 돕기 위하여 실시예를 들어 상세하게 설명하기로 한다. 다만 하기의 실시예는 본 발명의 내용을 예시하는 것일 뿐 본 발명의 범위가 하기 실시예에 한정되는 것은 아니다. 본 발명의 실시예는 당업계에서 평균적인 지식을 가진 자에게 본 발명을 보다 완전하게 설명하기 위해 제공되는 것이다.Hereinafter, examples will be described in detail to aid understanding of the present invention. However, the following examples are merely illustrative of the contents of the present invention, but the scope of the present invention is not limited to the following examples. The embodiments of the present invention are provided to more completely explain the present invention to those skilled in the art.
<< 준비예preparation example 1> 쇠뜨기 잎 추출물 제조 1> Manufacture of horsetail leaf extract
1. 실험 시약 및 세포 배양1. Experimental reagents and cell culture
항-디니트로페닐(dinitrophenyl, DNP)-IgE (Cat No. D8406), DNP-human serum albumin (HSA) (Cat No. A6661)은 Sigma사 (미국)에서 구입하였다. 인간 비만세포주인 RBL-2H3 세포 (한국세포주은행에서 구입)는 열에 의해 불활성화한 10% FBS가 첨가된 Gibco사 (미국)의 Dulbecco’s modified eagle medium (Cat No. 12800-017)에서 배양하였다.Anti-dinitrophenyl (DNP)-IgE (Cat No. D8406) and DNP-human serum albumin (HSA) (Cat No. A6661) were purchased from Sigma (USA). Human mast cell line RBL-2H3 cells (purchased from Korea Cell Line Bank) were cultured in Dulbecco's modified eagle medium (Cat No. 12800-017) from Gibco (USA) supplemented with 10% FBS inactivated by heat.
2. 쇠뜨기잎 추출물(2. Horsetail leaf extract ( EELEAEELEA ) 제조 ) manufacturing
쇠뜨기 잎을 70℃에서 5시간 동안 정제된 물로 2회 추출하였다. 상기 추출물을 여과하고 동결 건조시킨 다음 4℃에서 보관하였다. 출발 원료로부터의 건조 추출물의 수율은 약 17.06 % 정도이다.Horsetail leaves were extracted twice with purified water at 70°C for 5 hours. The extract was filtered, lyophilized and stored at 4°C. The yield of dry extract from the starting material is about 17.06%.
<< 실시예Example 1> 비만세포에서 쇠뜨기 잎 추출물의 히스타민 유리 억제효과 확인 1> Confirmation of the inhibitory effect of horsetail leaf extract on histamine release in mast cells
비만세포로부터 히스타민 유리에 대한 억제효과를 확인하기 위하여 RBL-2H3 세포와 쥐 복강 비만세포 RPMCs(rat peritoneal mast cells)를 항-DNP-IgE로 감작시킨 후, DNP-HSA를 처리하여 활성화시킴으로써 세포 내 과립의 주 함유물질이자 알레르기 유발물질인 히스타민을 유리시켰다. 활성화에 앞서 각각의 비만세포들에는 다양한 농도의 쇠뜨기 잎 추출물(EELEA)을 전 처리하였다. 활성화된 비만세포의 배양액을 회수하여 실험에 사용하였다. In order to confirm the inhibitory effect on histamine release from mast cells, RBL-2H3 cells and rat peritoneal mast cells (RPMCs) were sensitized with anti-DNP-IgE and treated with DNP-HSA to activate them. Histamine, a major component of the granules and an allergen, was released. Prior to activation, each mast cell was pre-treated with various concentrations of horsetail leaf extract (EELEA). A culture solution of activated mast cells was collected and used in the experiment.
즉, 에펜돌프 튜브에 시료 200μL을 취하여 0.1N 염산 80μL과 60％ 과염소산 용액 20μL을 혼합한 후에 원심분리(13,000g, 20분, 5415R, Eppendorf사)를 하였다. 그 상등액 200μL을 취해 5N NaOH 용액 100μL, n-부탄올(n-butanol) 800μL, 5M NaCl 200μL을 혼합한 시험관에 넣고 이를 진탕한 후 원심분리(13,000g, 20분)를 수행하였다. 상기 시험관에서 부탄올(butanol)층 500μL을 취해 0.1N 염산 200μL, n-헵탄(n-heptane) 500μL을 가하여 진탕하고 다시 원심분리(13,000g, 20분)를 수행하여 수층을 얻었다. 얻어진 수층 150μL에 1N NaOH 40μL, 1％ o-프탈디알데하이드(o-phthaldialdehyde) 용액(Sigma사, Cat No. P1378) 10μL을 가하여 혼합하고 5분 동안 방치한 다음, 3N 염산 20μL을 추가하여 방출파장(emission wavelength) 440nm, 여기파장(excitation wavelength) 360nm에서 형광강도를 형광분석기(GEMINIEM, Molecular Devices 사)를 이용하여 측정하였다.That is, 200 μL of the sample was taken in an Eppendorf tube, mixed with 80 μL of 0.1 N hydrochloric acid and 20 μL of a 60% perchloric acid solution, and then centrifuged (13,000 g, 20 minutes, 5415R, Eppendorf). 200 μL of the supernatant was placed in a test tube in which 100 μL of a 5N NaOH solution, 800 μL of n-butanol, and 200 μL of 5M NaCl were mixed, shaken, and centrifuged (13,000 g, 20 minutes). In the test tube, 500 μL of the butanol layer was taken, 200 μL of 0.1 N hydrochloric acid and 500 μL of n-heptane were added, shaken, and centrifuged again (13,000 g, 20 minutes) to obtain an aqueous layer. To 150 μL of the obtained aqueous layer, 40 μL of 1N NaOH and 10 μL of 1% o-phthaldialdehyde solution (Sigma, Cat No. P1378) were added, mixed, left for 5 minutes, and then 20 μL of 3N hydrochloric acid was added to determine the emission wavelength. Fluorescence intensity was measured at an emission wavelength of 440 nm and an excitation wavelength of 360 nm using a fluorescence analyzer (GEMINIEM, Molecular Devices).
그 결과, 도 1에 나타난 바와 같이, 활성화된 비만세포에서 많은 양의 히스타민이 유리되었으나, 쇠뜨기 잎 추출물(EELEA)을 처리한 경우, 농도 의존적으로 히스타민의 유리가 억제됨을 확인할 수 있다.As a result, as shown in FIG. 1, although a large amount of histamine was released from the activated mast cells, it was confirmed that the release of histamine was suppressed in a concentration-dependent manner when treated with horsetail leaf extract (EELEA).
특히, 상기 쇠뜨기 잎 추출물은 비교예로 사용된 덱사메타손(dexamethasone, Dexa)에 비해 낮은 농도에서 비슷한 수준의 히스타민의 유리 억제 효과를 나타내는 바, 이를 통해, 본 발명의 쇠뜨기 잎 추출물이 알레르기 질환에 효과가 있음을 확인할 수 있다.In particular, the horsetail leaf extract exhibits a similar level of histamine release inhibitory effect at a lower concentration than that of dexamethasone (Dexa) used as a comparative example, and through this, the horsetail leaf extract of the present invention is effective in allergic diseases. can confirm that there is
<< 실시예Example 2> 비만세포에서 세포 내 칼슘에 대한 쇠뜨기 잎 추출물의 효과 확인 2> Confirmation of the effect of horsetail leaf extract on intracellular calcium in mast cells
칼슘은 세포 내 2차 전달물질로서 생리활성의 조절에 중요한 역할을 하고, 비만세포의 탈과립을 조절하는 신호전달 물질로 잘 알려져 있다. 따라서 세포 내 칼슘의 양이 증가하면 비만세포가 탈과립되고, 반대로 칼슘의 양이 감소하면 비만세포의 탈과립이 억제된다. 따라서 세포 내 칼슘에 대한 쇠뜨기 잎 추출물 효과의 관찰을 통해 쇠뜨기 잎 추출물의 비만세포에서 히스타민 유리 작용기전을 확인할 수 있다. Calcium, as an intracellular secondary transmitter, plays an important role in regulating physiological activity and is well known as a signaling material regulating degranulation of mast cells. Therefore, when the amount of intracellular calcium increases, mast cells degranulate, and conversely, when the amount of calcium decreases, degranulation of mast cells is inhibited. Therefore, through observation of the effect of horsetail leaf extract on intracellular calcium, the mechanism of histamine release in mast cells of horsetail leaf extract can be confirmed.
RBL-2H3 세포에 항-DNP-IgE와 DNP-HSA를 각각 처리함으로써 활성화된 비만세포에서 세포 내 칼슘 양과 쇠뜨기 잎 추출물을 처리한 후 세포 내 칼슘의 양은 Fluo-3, AM(Invitrogen사, Cat No. F1242)을 이용하여 형광염색한 후 형광분석기로 측정하였다.In mast cells activated by treating RBL-2H3 cells with anti-DNP-IgE and DNP-HSA, respectively, the amount of intracellular calcium and the amount of intracellular calcium after treatment with horsetail leaf extract were measured by Fluo-3, AM (Invitrogen, Cat No. After fluorescence staining using F1242), it was measured with a fluorescence analyzer.
그 결과, 도 2에 나타난 바와 같이, 활성화된 비만세포는 급격한 세포 내 칼슘의 증가를 나타내었으나, 쇠뜨기 잎 추출물을 처리한 군에서 유의적으로 세포 내 칼슘의 양 증가가 현저하게 감소하는 것으로 나타났다. 이를 통해 쇠뜨기 잎 추출물이 칼슘의 양을 감소시켜 비만세포의 탈과립을 억제함으로써 알레르기 치료에 효과가 있음을 확인할 수 있다.As a result, as shown in FIG. 2, the activated mast cells showed a rapid increase in intracellular calcium, but the increase in the amount of intracellular calcium was significantly reduced in the group treated with horsetail leaf extract. Through this, it can be confirmed that the horsetail leaf extract is effective in treating allergy by suppressing degranulation of mast cells by reducing the amount of calcium.
특히, 상기 쇠뜨기 잎 추출물은 비교예로 사용된 세포 내 칼슘 저해제인 BAPTA-AM (1,2-Bis(2-aminophenoxy)ethane-N,N,N′,N′-tetraacetic acid tetrakis (acetoxymethyl ester))에 비해 낮은 농도에서 비슷한 수준으로 비만세포의 탈과립을 억제함을 확인할 수 있다.In particular, the horsetail leaf extract is BAPTA-AM (1,2-Bis (2-aminophenoxy) ethane-N, N, N', N'-tetraacetic acid tetrakis (acetoxymethyl ester), an intracellular calcium inhibitor used as a comparative example. ), it can be confirmed that degranulation of mast cells is inhibited at a similar level at a low concentration compared to
<< 실시예Example 3> 비만세포에서 쇠뜨기 잎 추출물의 염증 유발 저해 효과 확인 3> Confirmation of anti-inflammatory effect of horsetail leaf extract on mast cells
비만세포에서 유리되거나 새로 합성되어 분비됨으로써 염증성 알레르기를 일으키는 생리활성물질인 TNF-α 및 IL-4와 같은 염증 유발성 사이토카인의 발현에 대한 쇠뜨기 잎 추출물의 효과를 확인하기 위해, 비만세포를 항-DNP-IgE로 감작시킨 후, DNP-HSA로 활성화하여 염증 유발성 사이토카인의 분비를 촉진시킨 다음 효소결합 면역흡착 분석법을 이용하여 각각의 분비량을 측정하였다.In order to confirm the effect of horsetail leaf extract on the expression of pro-inflammatory cytokines such as TNF-α and IL-4, which are physiologically active substances that cause inflammatory allergy by being secreted from mast cells or newly synthesized and secreted, mast cells were treated with anti-inflammatory drugs. After sensitization with DNP-IgE, secretion of pro-inflammatory cytokines was promoted by activation with DNP-HSA, and the amount of each secretion was measured using enzyme-linked immunosorbent assay.
효소결합 면역흡착 분석법(ELISA)으로 배양액 내의 사이토카인 농도를 산출하기 위하여 이미 상품화 되어있는 kit (San Diego, BD biosciences 사)를 사용하였다. 간략히 방법을 기술하면, 항원이 부착되어 있는 well에 배양액과 농도별로 희석한 표준시료를 200μL을 넣고 방치하였다. 120분 후 세척액으로 3회 세척 후 1차 항체를 100μL 씩 넣었다. 잘 혼합하여 60분간 방치한 후 세척액으로 3회 세척한 후 2차 항체와 효소 시약을 섞은 혼합시약을 100μL씩 넣었다. 반응이 끝난 후 혼합물을 버리고 세척액으로 4회 세척 후 기질 용액을 100μL씩 넣고 빛을 차단한 실온 상태에서 20분간 방치하였다. 반응 후 정지시약(2N H2SO4)을 50μL 씩 넣어주어 반응을 정지하고, 450nm에서의 흡광도를 흡광분석기(Sunnyvale, Molecular devices 사)로 측정하였다.An already commercialized kit (San Diego, BD biosciences) was used to calculate the cytokine concentration in the culture medium by enzyme-linked immunosorbent assay (ELISA). To briefly describe the method, 200 μL of the standard sample diluted by the culture medium and concentration was added to the well to which the antigen was attached and left to stand. After 120 minutes, 100 μL of primary antibody was added after washing three times with washing solution. Mixed well, left for 60 minutes, washed three times with washing solution, and then added 100 μL of a mixed reagent of secondary antibody and enzyme reagent. After the reaction was over, the mixture was discarded and washed 4 times with a washing solution, into which 100 μL of each substrate solution was added and left for 20 minutes at room temperature with light blocked. After the reaction, the reaction was stopped by adding 50 μL of a stop reagent (2N H 2 SO 4 ), and the absorbance at 450 nm was measured with an absorbance analyzer (Sunnyvale, Molecular devices).
그 결과, 도 3에 나타난 바와 같이, 항-DNP-IgE와 DNP-HSA로 활성화시킨 RBL-2H3 세포에서 TNF-α 및 IL-4 사이토카인의 분비량이 증가하였으며, 쇠뜨기 잎 추출물을 농도별로 전 처리한 결과 쇠뜨기 잎 추출물이 농도 의존적으로 이들 사이토카인의 분비량을 감소시키는 것으로 나타났다. 또한, 대조군인 덱사메타손(Dexa)에 비해 더 낮은 농도에서 효과적으로 염증 유발성 사이토카인의 분비량을 감소시킴을 확인함으로써 쇠뜨기 잎 추출물이 덱사메타손에 비해 더 효과적으로 염증 유발을 저해시킴을 확인할 수 있다.As a result, as shown in FIG. 3, the secretion of TNF-α and IL-4 cytokines increased in RBL-2H3 cells activated with anti-DNP-IgE and DNP-HSA, and horsetail leaf extract was pre-treated at each concentration. As a result, it was found that horsetail leaf extract decreased the secretion of these cytokines in a concentration-dependent manner. In addition, it can be confirmed that horsetail leaf extract inhibits inflammation more effectively than dexamethasone by confirming that the secretion of inflammatory cytokines is effectively reduced at a lower concentration than that of the control group dexamethasone (Dexa).
<< 실시예Example 4> 국소 피부 알레르기 반응에 대한 쇠뜨기 잎 추출물의 효과 확인 4> Confirmation of the effect of horsetail leaf extract on local skin allergic reactions
항알레르기 효과를 갖는 약물을 개발할 때 많이 사용되는 수동형 국소 피부 알레르기 반응(passive cutaneous anaphylaxis, PCA)을 이용하여 쇠뜨기 잎 추출물의 피부 알레르기에 대한 효과를 실험하였다. PCA는 IgE에 의해 매개되는 알레르기 반응으로 항체를 국소 피부에 피내주사하고 48시간 후 항원을 생쥐의 꼬리 정맥으로 투여하여 인위적으로 알레르기 반응을 일으키는 실험 방법이다. 이 경우 항체 주사부위에서 항원-항체 반응이 일어나 그 주변에 존재하는 비만세포가 활성화되어 히스타민이 분비되고 국소적으로 알레르기 반응이 일어난다. 따라서 이에 대해 쇠뜨기 잎 추출물의 농도를 달리하여 경구 투여한 뒤 생쥐의 발적 정도와 귀의 부종 정도를 관찰하였다.The effect of horsetail leaf extract on skin allergy was tested using passive cutaneous anaphylaxis (PCA), which is frequently used when developing drugs with anti-allergic effects. PCA is an allergic reaction mediated by IgE, which is an experimental method that artificially induces an allergic reaction by injecting an antibody intradermally into the local skin and administering the antigen 48 hours later into the tail vein of mice. In this case, an antigen-antibody reaction occurs at the antibody injection site, and mast cells present around it are activated to secrete histamine and cause an allergic reaction locally. Therefore, after oral administration of horsetail leaf extract at different concentrations, the degree of redness and swelling of the ears of mice were observed.
그 결과, 도 4에 나타난 바와 같이, 쇠뜨기 잎 추출물을 처리한 결과, 농도가 높을수록 발적 부위가 작아지는 것으로 나타난 바, 이를 통해 쇠뜨기 잎 추출물이 농도 의존적으로 국소 피부 알레르기 반응을 억제함을 확인할 수 있다.As a result, as shown in FIG. 4, as a result of treating the horsetail leaf extract, it was found that the higher the concentration, the smaller the redness area. Through this, it can be confirmed that the horsetail leaf extract suppresses the local skin allergic reaction in a concentration-dependent manner. there is.
<< 실시예Example 5> 비만세포 내에서 쇠뜨기 잎 추출물의 세포독성 실험 5> Cytotoxicity test of horsetail leaf extract in mast cells
쇠뜨기 잎 추출물의 세포독성을 확인하기 위하여 MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide) 실험을 하기와 같이 실시하였다. MTT 용액은 살아있는 세포에서 미토콘드리아의 디하이드로게나아제(dehydrogenases)에 의해서 포르마잔(formazan)을 형성하여 세포의 생존 여부를 확인할 수 있다. In order to confirm the cytotoxicity of horsetail leaf extract, MTT (3-(4,5-dimethyl thiazol-2-yl)-2,5-diphenyltetrazolium bromide) experiment was performed as follows. The MTT solution forms formazan by mitochondrial dehydrogenases in living cells, thereby confirming the viability of the cells.
세포독성 확인을 위해 RBL-2H3 세포를 96 웰 플레이트에 3×104세포/웰로 37℃에서 배양한 후, 쇠뜨기 잎 추출물을 각각 0.1 ~ 1000μg/mL로 처리하고 10시간 동안 배양하였다. 10시간 후 각 웰에 20μL의 MTT 용액을 첨가하고 2시간 동안 추가로 배양한 후 배양액을 제거하고 100μL의 디메틸설폭사이드(dimethylsulfoxide)를 첨가한 후 570nm에서 흡광도를 측정하였다.To confirm cytotoxicity, RBL-2H3 cells were cultured in a 96-well plate at 3×10 4 cells/well at 37° C., treated with horsetail leaf extract at 0.1 to 1000 μg/mL, and cultured for 10 hours. After 10 hours, 20 μL of MTT solution was added to each well, and after further incubation for 2 hours, the culture medium was removed, 100 μL of dimethylsulfoxide was added, and absorbance was measured at 570 nm.
그 결과, 도 5에 나타난 바와 같이, 쇠뜨기 잎 추출물은 1000μg/mL의 농도까지 세포독성을 나타내지 않아, 인체에 무해함을 확인하였다.As a result, as shown in FIG. 5, the horsetail leaf extract did not exhibit cytotoxicity up to a concentration of 1000 μg/mL, confirming that it was harmless to the human body.
이상으로 본 발명 내용의 특정한 부분을 상세히 기술하였는 바, 당업계의 통상의 지식을 가진 자에게 있어서, 이러한 구체적 기술은 단지 바람직한 실시양태일 뿐이며, 이에 의해 본 발명의 범위가 제한되는 것이 아닌 점은 명백하다. 즉, 본 발명의 실질적인 범위는 첨부된 청구항들과 그것들의 등가물에 의하여 정의된다.Having described specific parts of the present invention in detail above, it is clear to those skilled in the art that these specific descriptions are only preferred embodiments, and the scope of the present invention is not limited thereby. do. That is, the substantial scope of the present invention is defined by the appended claims and their equivalents.
Claims (7)
상기 추출물은,
물, C1-C4 알코올 또는 이의 혼합물을 추출용매로 하여 추출된 것을 특징으로 하는 알레르기 질환 예방 또는 치료용 약학 조성물.According to claim 1,
The extract is
A pharmaceutical composition for preventing or treating allergic diseases, characterized in that the extraction is performed using water, C1-C4 alcohol, or a mixture thereof as an extraction solvent.
상기 조성물은,
비만세포의 탈과립을 억제하고 항염증 활성을 가지는 것을 특징으로 하는 알레르기 질환 예방 또는 치료용 약학 조성물.According to claim 1,
The composition,
A pharmaceutical composition for preventing or treating allergic diseases, characterized in that it inhibits degranulation of mast cells and has anti-inflammatory activity.
상기 조성물은,
국소적 피부 알레르기 반응을 억제하는 것을 특징으로 하는 알레르기 질환 예방 또는 치료용 약학 조성물.According to claim 1,
The composition,
A pharmaceutical composition for the prevention or treatment of allergic diseases characterized by suppressing local skin allergic reactions.
상기 알레르기 질환은,
비만세포 매개 알레르기 질환인 것을 특징으로 하는 알레르기 질환 예방 또는 치료용 약학 조성물.According to claim 1,
The allergic disease,
A pharmaceutical composition for preventing or treating allergic diseases, characterized in that they are mast cell-mediated allergic diseases.
상기 알레르기 질환은,
접촉피부염, 아토피피부염, 천식, 알레르기성 결막염, 치주염, 비염, 중이염, 인후염, 편도염, 폐렴, 위궤양, 위염, 크론병, 대장염, 치질, 통풍, 강직성 척추염, 류마티스 열, 루푸스, 섬유근통(fibromyalgia), 건선관절염, 골관절염, 류마티스 관절염, 견관절주위염, 건염, 건초염, 건주위염, 근육염, 간염, 방광염, 신장염, 쇼그렌 증후군(sjogren's syndrome), 아나필락틱 쇼크(anaphylactic shock), 다발성 경화증, 급성 염증, 만성 염증질환, 두드러기, 고초열, 소화관 알레르기, 약제 알레르기, 식품 알레르기 및 화분증으로 이루어진 군에서 선택되는 하나 이상인 것을 특징으로 하는 알레르기 질환 예방 또는 치료용 약학 조성물.According to claim 5,
The allergic disease,
Contact dermatitis, atopic dermatitis, asthma, allergic conjunctivitis, periodontitis, rhinitis, otitis media, sore throat, tonsillitis, pneumonia, gastric ulcer, gastritis, Crohn's disease, colitis, hemorrhoids, gout, ankylosing spondylitis, rheumatic fever, lupus, fibromyalgia, Psoriatic arthritis, osteoarthritis, rheumatoid arthritis, periarthritis, tendonitis, tenosynovitis, periarthritis, myositis, hepatitis, cystitis, nephritis, sjogren's syndrome, anaphylactic shock, multiple sclerosis, acute inflammation, chronic inflammation A pharmaceutical composition for preventing or treating allergic diseases, characterized in that at least one selected from the group consisting of disease, urticaria, hay fever, digestive tract allergy, drug allergy, food allergy and hay fever.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210107041A KR20230025054A (en) | 2021-08-13 | 2021-08-13 | Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020210107041A KR20230025054A (en) | 2021-08-13 | 2021-08-13 | Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20230025054A true KR20230025054A (en) | 2023-02-21 |
Family
ID=85328156
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020210107041A KR20230025054A (en) | 2021-08-13 | 2021-08-13 | Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR20230025054A (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130106062A (en) | 2012-03-19 | 2013-09-27 | 김윤영 | Antibacterial composition obtained from natural plants and products comprising the same |
-
2021
- 2021-08-13 KR KR1020210107041A patent/KR20230025054A/en not_active Application Discontinuation
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20130106062A (en) | 2012-03-19 | 2013-09-27 | 김윤영 | Antibacterial composition obtained from natural plants and products comprising the same |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9241964B2 (en) | Composition from Sphaeranthus indicus and Garcinia mangostana for the control of metabolic syndrome | |
| KR102119368B1 (en) | Pharmaceutical Composition comprising Elaeocarpusin for Preventing or Treating of Mast Cell mediated Allergic Disease | |
| US5861433A (en) | Prevention and improvement of inflammation caused by leucotriene B4 | |
| KR101710474B1 (en) | Gallamide derivatives and use thereof | |
| JP4724824B2 (en) | Use of rare sugars to suppress the proliferation of T lymphocytes | |
| KR101160488B1 (en) | A pharmaceutical composition comprising extract of Lilium lancifolium for prevention and treatment of inflammatory diseases and asthma | |
| KR101337389B1 (en) | Food and pharmaceutical composition for anti-inflammation comprising extract of chinese medicine mixture as effective component | |
| KR101594115B1 (en) | Composition Comprising 1,2,4,5-tetramethoxybenzene for Preventing or Treating Allergic Disease | |
| KR20200048057A (en) | Antiinflammatory composition comprising Locusta migratoria extract | |
| JP2018516986A (en) | A composition for preventing or treating arthritis comprising an extract of Usubanokiri Moku as an active ingredient | |
| JPWO2003101464A1 (en) | Anti-inflammatory agents, allergic disease preventive or ameliorating agents and functional foods | |
| KR20230025054A (en) | Composition for preventing or treating allergic disease comprising extract from the leaf of equisetum arvense l. | |
| KR20200145757A (en) | A composition for preventing, improving or treating alcoholic gastritis comprising fraction of Apios Americana tuber extract and a method for preparing the same | |
| KR102505789B1 (en) | Pharmaceutical composition for anti-inflammation | |
| KR20230025055A (en) | Composition for preventing or treating allergic disease comprising extract from the stem of farfugium japonicum (l.) kitam. | |
| KR20230025053A (en) | Composition for preventing or treating allergic disease comprising extract of commelina communis l. | |
| KR101534498B1 (en) | Composition comprising the extract of Ceramium boydenii for preventing and treating inflammatory diseases | |
| KR101680013B1 (en) | Pharmaceutical composition for preventing or treating allergic diseases comprising extrat of Pterocarpus indicus Willd as an active ingredient | |
| KR101849338B1 (en) | A pharmaceutical composition comprising Kaempferol-3-O-rhamnopyranoside or pharmaceutically acceptable salt thereof as an active ingredient for prevention or treatment of inflammatory diseases, allergic diseases or malaria | |
| KR20160083610A (en) | A compound isolated from Amomi Tsao-ko and anti-inflammatory use thereof | |
| BR112020023816A2 (en) | composition for the prevention or treatment of allergic disease including inotodiol compound as active ingredient | |
| KR20140142580A (en) | Composition for prevention and treatment of inflammatory diseases comprising N-trans-ρ-caffeoyl tyramine compound isolated from Tribulus terrestris | |
| US8883226B2 (en) | Pharmaceutical composition for the prevention and treatment of inflammatory disease or asthma containing an extract of Decaspermum fruticosum | |
| KR20160008459A (en) | a composition comprising an extract of Gynura procumbens as an active ingredient for preventing or treating inflammation or allergy | |
| KR102352936B1 (en) | Composition for preventing and treating inflammatory bowel disease comprising sagassum serratifolium extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| E902 | Notification of reason for refusal |